Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2009-11-10
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255010, C544S360000, C544S365000, C544S384000, C544S386000, C544S391000
Reexamination Certificate
active
07615556
ABSTRACT:
The present application describes modulators of MIP-1α of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5aand R5bare as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
REFERENCES:
patent: 5847148 (1998-12-01), Jacobsen et al.
patent: 6391865 (2002-05-01), Baroudy et al.
patent: 2003/0162764 (2003-08-01), Castelhano et al.
patent: 2003/0229067 (2003-12-01), Castelhano et al.
patent: 4243858 (1994-06-01), None
patent: 0771565 (1997-05-01), None
patent: 0838460 (1998-04-01), None
patent: 2001/354657 (2000-12-01), None
patent: 2001-354657 (2001-12-01), None
patent: WO 92/15304 (1992-09-01), None
patent: WO 94/25437 (1994-11-01), None
patent: WO 95/34311 (1995-12-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 98/17625 (1998-04-01), None
patent: WO 99/08697 (1999-02-01), None
patent: WO 99/08699 (1999-02-01), None
patent: 99/11657 (1999-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/022835 (2003-03-01), None
patent: WO 03/092688 (2003-11-01), None
patent: WO 2004/037796 (2004-05-01), None
patent: WO 2004/076418 (2004-09-01), None
patent: WO 2004/113323 (2004-12-01), None
patent: WO 2005/003127 (2005-01-01), None
patent: WO 2005/056015 (2005-06-01), None
patent: WO 2005/118579 (2005-12-01), None
patent: WO 2006/013073 (2006-02-01), None
Baraldi, P. et al., “Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7receptor”, J. Med. Chem., vol. 46, pp. 1318-1320 (2003).
Carson, K. et al., “CCR1 Antagonists”, Annual Reports in Medicinal Chemistry, vol. 39, pp. 149-158 (2004).
Lang, L. et al., (Database Beilstein, Beilstein Institute for Organic Chemistry, BRN#: 8854794), J. Labelled Compd. Radiopharm., vol. 44, pp. S21-S23 (2001).
Oshiro, Y. et al., “Novel cerebroprotective agents with central nervous system stimulating activity. 2. Synthesis and pharmacology of the 1-(acylamino)-7-hydroxyindan derivatives”, J. Med. Chem., vol. 34, No. 7, pp. 2014-2023 (1991).
Pessoa-Mahana, H. et al., “Synthesis of 4-arylpiperazine derivatives of moclobemide: Potential antidepressants with a dual mode of action”, Synthetic Communications, vol. 34, No. 14, pp. 2513-2521 (2004).
Richardson, T. et al., “Synthesis and structure -activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor”, J. Med. Chem., vol. 47, pp. 744-755 (2004).
Tiwari, M., (Database Beilstein, Beilstein Institute for Organic Chemistry, BRN#: 943608, 944316), J. Indian Chem. Soc., vol. 53, pp. 310-311 (1976).
Carter Percy H.
Cavallaro Cullen L.
De Lucca George V.
Bogie Terence J.
Bristol--Myers Squibb Company
Korsen Elliott
Leeser Erich A
Wilson James O
LandOfFree
Piperazinyl derivatives as modulators of chemokine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinyl derivatives as modulators of chemokine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl derivatives as modulators of chemokine receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107520